DexCom's fair value estimate has been raised from $85.24 to $91.64, reflecting a moderate uplift in the price target range currently referenced for the stock. Several firms, including Raymond James, TD Cowen, Citi, Stifel, Mizuho, and Deutsche Bank, have lifted their price targets into an $88 to $96 range, citing strong second-quarter results, margin upside, and growth prospects in continuous glucose monitoring. In contrast, BofA, Canaccord, and Barclays reduced their targets in May, with Barclays maintaining an Underweight rating. The company also reported second-quarter 2026 results that supported a higher full-year outlook, received Health Canada authorization for the Dexcom G7 15 Day system, and was selected as the first participant in the FDA TEMPO Pilot Program. Additionally, DexCom announced a new share repurchase authorization of up to $1 billion through June 30, 2027.
DexCom IncFair value estimate raised and multiple analysts lifted price targets, citing strong Q2 results and margin upside.